Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028

According to our new research study on "Enzymatic DNA Synthesis Market" Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product Type, Application, Technology, and End User," is expected to grow from US$ 240.96 million in 2022 to US$ 2,244.88 million by 2028; it is estimated to record a CAGR of 45.1% during 2022-2028. Key factors driving the growth of this market are the rising prevalence of genetic disorders and the surging number of product launches.

Down syndrome, autism spectrum disorder, cancer, diabetes, cystic fibrosis, and sickle cell anemia are a few of the commonly known genetic disorders. Per the Global Genes, more than 10,000 different genetic and rare diseases have been identified, and ~400 million people suffer from rare diseases. Some genetic disorders cause symptoms at birth, while others develop over time.

Get Exclusive Sample Pages of Enzymatic DNA Synthesis Market @: https://www.premiummarketinsights.com/sample/TIP00073709?utm_source=OpenPr&utm_medium=10640

The List of Companies -
1. Telesis Bio Inc
2. Evonetix
3. Ansa Biotechnologies, Inc.
4. Camena Bio
5. GenScript Biotech Corp.
6. Molecular Assemblies
7. DNA Script
8. Touchligh
9. Synbio Technologies
10. Twist Bioscience

Based on product type is segmented into custom DNA synthesis and DNA library synthesis. In terms of application, the market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and other applications. By end user is divided into academic & research institutes, biotechnology & pharmaceutical companies, diagnostic laboratories, and others. Based on technology is segmented into SOLA, CRISPR, PCR, and others. By geography is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of APAC), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of MEA), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

The global burden of genetic diseases appears to be increasing. According to the National Center for Biotechnology Information (NCBI), a US-based medical organization, as of November 2021, genetic disorders were identified in 9.4% of pediatric patients, with 44.7% being critically ill newborns. In addition, 13.17 million patients in the US suffer from unique genetic disorders. According to the Centers for Disease Control and Prevention (CDC) 2022 report, sickle cell disease affects ~100,000 Americans, and it occurs in 1 in 356 African American births. Cystic fibrosis, another common genetic disease worldwide, affects ~30,000 people in the US, and ~1,000 new cases are treated annually. Enzymatic DNA synthesis is a well-established DNA synthesis technique useful in synthetic biology, genetic engineering, and therapeutic antibody studies. In conjunction with enzymatic assays, DNA synthesis shows greater diagnostic possibilities. This method provides important information about people at risk and helps them make important decisions regarding disease diagnosis and medication. Hence, with the rising prevalence of genetic disorders across the world, people are becoming more aware of the need for the early detection of these genetic flaws, which propels the growth.

Access full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/enzymatic-dna-synthesis-market

Surging Number of Product Launches Drives Growth
Advancements in medical technologies and an increase in investments in R&D by manufacturers have resulted in the launch of various modern systems for genetic and molecular biology studies. Companies in the enzymatic DNA synthesis market are involved in different product development activities.

In April 2022, DNA Script launched a new program for the customers of its SYNTAX System. Under this program, organizations receive early access to the latest advancements in their EDS technology. To add to the DNA Scriptors Early Access Program, the members already include the London Biofoundry and the BASE facility at the University of Queensland (UQ), Australia.

In November 2021, OriCiro Genomics Inc. launched the OriCiro Cell-Free Switching system.
In June 2021, DNA Script commercially launched its SYNTAX platform with the first product-the SYNTAX System. This system is the first benchtop nucleic acid printer powered by enzymatic DNA synthesis (EDS) technology. The SYNTAX System is a fully integrated, automated printer that synthesizes 96 DNA oligos in parallel, each of length of up to 60 nucleotides, and delivers them ready for use in molecular biology and genomics workflows, eliminating the need for additional handling.

In January 2021, Codex DNA, Inc. signed a strategic collaboration and licensing agreement with Pfizer to access and further develop the novel EDS technology of Codex DNA for its potential application in Pfizer's mRNA-based vaccines and other biopharma products.

Such developments help end users meet the rising demand for technically advanced systems that can efficiently manage data and provide accurate results, thereby boosting the market growth.
Growing Demand for Personalized Medicine and DNA Data Storage will Drive Enzymatic DNA Synthesis Market Growth During Forecast Period

Personalized medicine revolves around improving healthcare by harnessing early disease detection, preventive medicine, rational drug discovery and development, and therapy monitoring. The genetic profile of a patient assists doctors in precisely calculating a patient's susceptibility to specific diseases and allows them to prescribe the patient a proper medication with reduced side effects. The bottom-up synthetic biology approach is considered more relevant for developing personalized medicine as it offers more flexibility in building a semisynthetic cell from molecular building blocks for a desired application. Enzymatic DNA synthesis is expected to make a significant contribution to personalized medicine. It can be used to identify any possible mutations or gene variants affecting a patient's response to a particular drug/treatment by analyzing the patient's genome sequencing or microarray gene expression. Moreover, enzymatic DNA synthesis may furnish better conclusions in the prior identification of infection. Therefore, personalized medicine, especially for treating rare diseases and genetic disorders, is expected to bring new trends in the enzymatic DNA synthesis market.

New storage technologies are required to keep up with the global needs of data generation. Genetic code are perceived to be million-times more efficient at storing data than existing solutions, which are expensive, and consume immense power and space. DNA as a high-density data storage medium can drive breakthroughs in next-generation biosensing and bio-recording technology, and digital storage. DNA data storage is experiencing incredible growth with even giants from non-biological fields, such as Microsoft, entering the space. Enzymatic synthesis of DNA is considered to be a promising approach. Enzymatic systems synthesize DNA that records rapidly changing environmental signals directly into DNA sequences, a method that could change how scientists study and record neurons in the brain. Thus, growing efforts to harness multiplex enzymatic oligonucleotide synthesis in the context of important applications such as digital data storage will usher in a new era of scientific research and biotechnology.

Order a copy of this research Enzymatic DNA Synthesis Market research report at @: https://www.premiummarketinsights.com/buy/TIP00073709?utm_source=OpenPr&utm_medium=10640

Product Type-Based Insights
Based on product type, is segmented into custom DNA synthesis and DNA library synthesis. The DNA library synthesis segment held the largest market share in 2021. The custom DNA synthesis segment is anticipated to register the highest CAGR during the forecast period (2022-2028).

Application-Based Insights
Based on application, is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and other applications. The synthetic biology segment held the largest share of the market in 2021. The enzymatic DNA synthesis market for the therapeutic antibodies segment is expected to grow at the highest CAGR during the forecast period.

End User-Based Insights
Based on end user, is segmented into academic & research institutes, biotech & pharmaceutical companies, diagnostic laboratories, and others. The biotech & pharmaceutical companies segment held the largest share of the market in 2021. The academic & research institutes segment is anticipated to register the highest CAGR in the market during the forecast period (2022-2028).

Technology-Based Insights
Based on technology, is segmented into SOLA, CRISPR, PCR, and others. The PCR segment has the largest share in 2021 and is expected to continue a similar trend during the forecast period. On the other hand, the CRISPR segment is expected to witness the highest CAGR during the forecast period.

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.